MBX Biosciences (MBX) Accumulated Expenses (2023 - 2026)

MBX Biosciences has reported Accumulated Expenses for 4 years, with the latest figure at $2.3 million in Q1 2026.

• Quarterly Accumulated Expenses rose 90.14% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 90.14% YoY) and the FY2025 annual result came in at $12.3 million, up 431.24% from the prior year.
• Accumulated Expenses declined to $2.3 million in Q1 2026 per MBX's latest filing, from $12.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.3 million in Q4 2025 and troughed at $1.2 million in Q1 2025.
• A 4-year average of $4.6 million and a median of $2.4 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses declined 2.43% in 2024, then soared 431.24% in 2025.
• Over 4 years, Accumulated Expenses stood at $2.4 million in 2023, then retreated by 2.43% to $2.3 million in 2024, then jumped by 431.24% to $12.3 million in 2025, then plunged by 81.1% to $2.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.3 million, $12.3 million, and $8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.